The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial
Reveille JD, Hwang MC, Danve A, Kafka S, Peterson S, Lo KH, Kim L, Hsia EC, Chan EKH, Deodhar A. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. Clinical Rheumatology 2020, 40: 1331-1341. PMID: 32926247, DOI: 10.1007/s10067-020-05342-7.Peer-Reviewed Original ResearchConceptsHealth-related qualityDisease activityWeek 52Work Limitations QuestionnaireIntravenous golimumabWeeks 0Week 16Functioning outcomesEQ-5D-5L indexPlacebo-crossover groupProductivity loss scoresEffective treatment optionVisual analog scaleConclusionsIn patientsPlacebo groupSpondylitis QualityAdult patientsAnalog scaleEQ-VASWeek 28Treatment optionsProductivity outcomesWeek 8GolimumabHRQoL